Ginkgo Bioworks Inc., which calls itself an “organism design” company, has agreed to go public in a $17.5 billion merger with a blank-check firm backed by former Hollywood executive Harry Sloan.

Today Ginkgo Bioworks announced a new partnership with Google Cloud to build a generative AI platform for engineering biology and for biosecurity.

Ginkgo, under a grant from the Bill & Melinda Gates Foundation, will work to develop a live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria...

Pfizer will leverage Ginkgo’s proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas.

Here’s how four startups are programming biology to develop new products in medicine, energy, food and more.

We aim to deliver revolutionary advances in on-demand protein manufacturing by leveraging Cell-Free Protein Synthesis (CFPS) to enable rapid, high-yield, distributed production of human therapeutic...

We’re inspired and heartened by the tremendous public health response to COVID-19, and recognize that a similar scale of effort is needed by the biotech community to find long-term solutions to this...

Barry Canton, the CTO of Ginkgo Bioworks, the leading horizontal platform for cell programming and biosecurity, discusses how large language models can be tr...

We are excited to announce two new acquisitions today: Altar, a French biotechnology company that has developed a proprietary adaptive evolution platform, and Circularis, a biotechnology company with...

We will apply our expertise and capabilities in cell engineering, ultra high-throughput multiplexed screening, protein characterization and process optimization to improve production efficiency and...

UPDATE: After publishing this blog, Ginkgo has determined that our NGS machines can be used for even higher priority uses to help communities respond to COVID-19. Please note we are continuing with...

Ginkgo’s expertise in high throughput exploration of genetic design spaces complements Arbor’s in-house capabilities, and the collaboration is expected to accelerate Arbor’s precision editor optimi...

What’s the chemistry between generative AI and biotech? Anna Marie Wagner, SVP, Head of AI, Ginkgo Bioworks, shares why biology is going to be a significant ...

Novo Nordisk and Ginkgo have created a flexible and scalable new model for their R&D partnership. Together, we aim to improve the manufacturing of Novo Nordisk's medicines for serious chronic...

Ginkgo Bioworks has raised $719 million since it launched in 2008 to develop biotechnology solutions for industries as varied as cosmetics, agriculture and pharmaceuticals.

Today we are filing our S-4 with the Securities and Exchange Commission. We’d like to share with you excerpts from the letter that we are including in that document, which recognizes the history of...

Ginkgo may leverage the toolkit to address a wide range of customer needs and applications, including for customers developing microbiome based therapeutics.

/PRNewswire/ -- Benjamin Franklin Institute of Technology (BFIT), a private non-profit college offering affordable education for people seeking technical and...

Ginkgo Enzyme Services offers partners end-to-end support for the discovery, engineering, optimization, and scale-up of enzymes for diverse applications.

We’re thrilled to partner with Synplogen as we seek to grow our cell and gene therapy service offerings in Japan as well as support the vibrant and innovative Japanese bioeconomy more broadly.

Nosh.bio will leverage our Ginkgo Strain Optimization Services to screen for protein-producing fungi strains with superior sensorial profiles.

Today, we’re pleased to announce our completed acquisition of Zymergen. This is our largest acquisition to date!

Foremost will leverage Ginkgo’s bioproduction services to develop and commercialize a new technology to help upcycle billions of pounds of dairy co-products each year.

What if we could grow everything? Biology can. Ginkgo Bioworks is the organism company. Headquartered in Boston, Ginkgo Bioworks uses the most advanced technology…

This council of experts from across the biopharmaceutical industry will provide critical insight into the development of Ginkgo’s core platform service offerings across target discovery, drug...

Exacta will leverage Ginkgo’s end-to-end agricultural R&D services to run a fermentation optimization and scale-up program to enhance one of its crop protection products, FitoRoot®, paving the way...

We’re excited to continue our work with Novo Nordisk to help provide innovative treatment options for patients with diabetes, obesity, and other serious chronic diseases.

Dr. Jason Kelly is the co-founder and CEO of Ginkgo Bioworks which is a synthetic biology company programming cells for customers in the chemical, pharmaceut...

It’s not all dinosaurs and toxic sludge. Join us: https://jobs.lever.co/ginkgobioworks

Members of Congress visited Ginkgo’s Boston Seaport headquarters to discuss strategies for bolstering U.S. ability to compete in AI applications for biotechnology, as well as unlocking innovations in...

https://www.ginkgobioworks.com/investors/

QL AG will tap into Ginkgo’s extensive capabilities in strain engineering to support its goal of providing the market with high-quality nutritionally equivalent dairy proteins.

IARPA B24IC Research Contract We’re pleased to announce that we’ve been awarded a research contract from the Intelligence Advanced Research Projects Activity (IARPA), the research and development arm...

Today, we are pleased to announce a research partnership with Syngenta Seeds (“Syngenta”), one of the world’s leading agricultural technology companies. The focus of this partnership will be on...

This council of experts from across the biopharmaceutical industry will provide critical insight into the development of Ginkgo’s core platform service offerings across target discovery, drug...

Through this partnership, Factorial will leverage Ginkgo Enzyme Services to develop a novel isothermal DNA polymerase for use in their single-cell next-generation sequencing (NGS) library prep kit.

Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform Expect integration of Zymergen's...

In collaboration with Prokarium, Ginkgo will set out to engineer a bactofection platform for the delivery of RNA payloads to treat cancer patients.

President Obama delivers a speech at COP26 climate summit in Glasgow, Scotland.Don't Miss: Valley of Hype: The Culture That Built Elizabeth HolmesWATCH HERE:...

Barely a week after striking a $2.5 billion special purpose acquisition company deal to go public, Ginkgo Bioworks is going international. | Barely a week after striking a $2.5 billion SPAC deal to...

Through this multi-year collaboration, we’ll show Solvay how the  power of synthetic biology can enable  their development of more sustainable chemicals and materials, and contribute to the transit...

We are so excited to partner with Agrivalle on getting groundbreaking biological products into the hands of growers.

Get tickets to Grow with Ginkgo: Synthetic Biology for Climate Action, taking place 24/02/2022. RingCentral Events is your source for engaging events and experiences.

With this partnership, we aim to use our extensive capabilities in strain engineering to improve upon one of Visolis’ existing microbial strains.

The White House

Our partnership aims to help NAMUH produce complete infant formula products that are substantially comparable to human breast milk, down to the molecular level.

Our ASGCT presentations this year represent advances in large library screening in vivo and in vitro, the use of automation for high throughput genome engineering in iPSCs, and the application of...